New Eli Lilly Data Puts Verzenio In Breast Cancer Spotlight - Eli Lilly (NYSE:LLY)

Breakthrough Breast Cancer Pill Extends Survival in 7-Year Trial

A breakthrough therapy for advanced breast cancer also works well in the early stages, allegedly improving survival outcomes for patients. According to the pharmaceutical company Lilly Oncology, a phase 3 clinical trial has now confirmed that the Abemaciclib pill, sold under the brand name Verzenio, can significantly reduce the risk of relapse in some types of early breast cancer, which had spread to the lymph node. Results from the seven-year f…

Lilly raises stakes in Novartis battle with Verzenio data

Armed with new survival data for Verzenio in early breast cancer, Lilly hopes to keep the drug's nose in front of a fast-growing rival from Novartis.

Lilly says breast cancer drug extended survival in study

Treatment with Verzenio helped people with a common type of early breast cancer liver longer than those given standard hormone therapy.

New Eli Lilly Data Puts Verzenio In Breast Cancer Spotlight - Eli Lilly (NYSE:LLY)

Pharmaceutical advancements continue to reshape the landscape of cancer treatment, offering new hope for patients and altering market dynamics. Recent developments in innovative therapies demonstrate significant progress in survival outcomes for high-risk early breast cancer patients. Eli Lilly and Co. (NYSE:LLY) on Wednesday released topline results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial. Treatment with tw…

Abemaciclib Plus Endocrine Therapy Improves Survival in Patients With HR+/HER2– Breast Cancer

Abemaciclib enhances overall survival in high-risk HR+, HER2– early breast cancer, establishing its role as a standard adjuvant therapy.

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Results from the monarchE study showed a statistically significant OS improvement with abemaciclib plus ET for patients with HR+/HER2– early breast cancer.